Metabolic reprogramming and the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic targeting

Abstract

Metabolic reprogramming is a fundamental mechanism through which tumor cells reshape their energy metabolism to sustain rapid proliferation. It facilitates malignant growth by reprogramming key pathways, including glycolysis and amino acid metabolism. The tumor microenvironment (TME) is composed of tumor cells, stromal cells, and immune cells. The characteristics of hypoxia, acidity, and nutrient deficiency are mainly driven by the metabolic products and cytokines secreted by tumor cells. This metabolic pressure not only inhibits the functions of immune cells, but also further enhances immune evasion through nutrient competition. Targeting metabolic reprogramming can reverse immunosuppression within the TME and enhance the response to immunotherapy. This article systematically reviews the regulatory mechanisms of metabolic reprogramming in hepatocellular carcinoma and its impact on the TME, while also exploring therapeutic strategies based on metabolic interventions.

Keywords

Metabolic reprogramming / tumor microenvironment / hepatocellular carcinoma / targeted therapy / immunotherapy

References

[1] Chan YT,Wu J.Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma.Mol Cancer2024;23:189 PMCID:PMC11378508

[2] Allemani C, Matsuda T, Di Carlo V, et al.; CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.Lancet2018;391:1023-75 PMCID:PMC5879496

[3] Bray F,Sung H.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024;74:229-63

[4] Chan SL,Xu Y.The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.Lancet2025;406:731-78

[5] Rumgay H,de Martel C.Global, regional and national burden of primary liver cancer by subtype.Eur J Cancer2022;161:108-18

[6] Al Noshokaty T, Mesbah N, Abo-Elmatty D, Abulsoud A, Abdel-Hamed A. Hepatocellular carcinoma pathogenesis: epigenetics and relationship with cancer hallmarks.Rec Pharm Biomed Sci2022;6:136-57

[7] Hytiroglou P,Theise ND.Etiology, pathogenesis, diagnosis, and practical implications of hepatocellular neoplasms.Cancers2022;14:3670 PMCID:PMC9367411

[8] Mao JJ,Andrade CJ.Integrative oncology: addressing the global challenges of cancer prevention and treatment.CA Cancer J Clin2022;72:144-64

[9] Federico P,Giordano P.Immune checkpoint inhibitors in hepatocellular carcinoma: current status and novel perspectives.Cancers2020;12:3025 PMCID:PMC7603151

[10] Leowattana W,Leowattana P.Systemic treatment for unresectable hepatocellular carcinoma.World J Gastroenterol2023;29:1551-68 PMCID:PMC10037251

[11] Sankar K,Osipov A.Recent advances in the management of hepatocellular carcinoma.Clin Mol Hepatol2024;30:1-15 PMCID:PMC10776289

[12] Keenan BP,Kelley RK.Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.J Immunother Cancer2019;7:267 PMCID:PMC6798343

[13] Cantor JR.Cancer cell metabolism: one hallmark, many faces.Cancer Discov2012;2:881-98 PMCID:PMC3491070

[14] Han J,Chen Y.Recent metabolomics analysis in tumor metabolism reprogramming.Front Mol Biosci2021;8:763902 PMCID:PMC8660977

[15] Lin J,Jiang L.Progress in metabolism of the immune cells in tumor microenvironment.J Shanghai Jiaotong Univ2022;42:1122-30

[16] Foglia B,Sutti S.Metabolic reprogramming of HCC: a new microenvironment for immune responses.Int J Mol Sci2023;24:7463 PMCID:PMC10138633

[17] Hu N,Tao C,Rong W.The role of metabolic reprogramming in the tumor immune microenvironment: mechanisms and opportunities for immunotherapy in hepatocellular carcinoma.Int J Mol Sci2024;25:5584 PMCID:PMC11171976

[18] Yang F,Shaha A.Metabolic reprogramming and its clinical implication for liver cancer.Hepatology2023;78:1602-24 PMCID:PMC10315435

[19] Liu Q,Qi J.Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for HCC.Hepatology2025;81:1164-80 PMCID:PMC11902616

[20] Gao B,Lai X.Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications.Front Immunol2025;16:1592837 PMCID:PMC12075234

[21] Tennant DA,Gottlieb E.Targeting metabolic transformation for cancer therapy.Nat Rev Cancer2010;10:267-77

[22] Guerra L,Brenner D.Metabolic modulation of immunity: a new concept in cancer immunotherapy.Cell Rep2020;32:107848

[23] Shen KY,Xie SZ.Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.J Hematol Oncol2024;17:25 PMCID:PMC11057182

[24] DeBerardinis RJ,Hatzivassiliou G.The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.Cell Metab2008;7:11-20

[25] Elia I.Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism.Nat Metab2021;3:21-32 PMCID:PMC8097259

[26] Oura K,Tani J.Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review.Int J Mol Sci2021;22:5801 PMCID:PMC8198390

[27] Lv B,Ma D.Immunotherapy: reshape the tumor immune microenvironment.Front Immunol2022;13:844142 PMCID:PMC9299092

[28] Fu T,Wu SY.Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response.J Hematol Oncol2021;14:98 PMCID:PMC8234625

[29] Leone RD.Metabolism of immune cells in cancer.Nat Rev Cancer2020;20:516-31 PMCID:PMC8041116

[30] Ward PS.Metabolic reprogramming: a cancer hallmark even warburg did not anticipate.Cancer Cell2012;21:297-308 PMCID:PMC3311998

[31] Chang CH,O’Sullivan D.Metabolic competition in the tumor microenvironment is a driver of cancer progression.Cell2015;162:1229-41 PMCID:PMC4864363

[32] Liberti MV.The Warburg effect: how does it benefit cancer cells?.Trends Biochem Sci2016;41:211-8 PMCID:PMC4783224

[33] Vaupel P.Revisiting the Warburg effect: historical dogma versus current understanding.J Physiol2021;599:1745-57

[34] Deng X,Cheng M.Pyruvate dehydrogenase kinase 1 interferes with glucose metabolism reprogramming and mitochondrial quality control to aggravate stress damage in cancer.J Cancer2020;11:962-73 PMCID:PMC6959030

[35] Koppenol WH,Dang CV.Otto Warburg’s contributions to current concepts of cancer metabolism.Nat Rev Cancer2011;11:325-37

[36] Lunt SY.Aerobic glycolysis: meeting the metabolic requirements of cell proliferation.Annu Rev Cell Dev Biol2011;27:441-64

[37] Bouillaud F,Schwartz L.Warburg effect, glutamine, succinate, alanine, when oxygen matters.Biology2021;10:1000 PMCID:PMC8533123

[38] Zhang D,Huang H.Metabolic regulation of gene expression by histone lactylation.Nature2019;574:575-80 PMCID:PMC6818755

[39] Zhang D,Zhu Z.Lysine L-lactylation is the dominant lactylation isomer induced by glycolysis.Nat Chem Biol2025;21:91-9 PMCID:PMC11666458

[40] Rho H.Protein lactylation in cancer: mechanisms and potential therapeutic implications.Exp Mol Med2025;57:545-53 PMCID:PMC11958728

[41] Feng F,Chi Q.Lactylome analysis unveils lactylation-dependent mechanisms of stemness remodeling in the liver cancer stem cells.Adv Sci2024;11:e2405975 PMCID:PMC11481176

[42] Cai J,Cai Y.Lactylation-driven NUPR1 promotes immunosuppression of tumor-infiltrating macrophages in hepatocellular carcinoma.Adv Sci2025;12:e2413095 PMCID:PMC12120759

[43] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation.Science2009;324:1029-33 PMCID:PMC2849637

[44] Epstein T,Gillies RJ.Separation of metabolic supply and demand: aerobic glycolysis as a normal physiological response to fluctuating energetic demands in the membrane.Cancer Metab2014;2:7 PMCID:PMC4060846

[45] Inigo M,Burgess SC.Ins and outs of the TCA cycle: the central role of anaplerosis.Annu Rev Nutr2021;41:19-47

[46] Yang H,Niu Y.Interactions between the metabolic reprogramming of liver cancer and tumor microenvironment.Front Immunol2025;16:1494788 PMCID:PMC11868052

[47] DeBerardinis RJ,Daikhin E.Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis.Proc Natl Acad Sci U S A2007;104:19345-50 PMCID:PMC2148292

[48] Eniafe J.The functional roles of TCA cycle metabolites in cancer.Oncogene2021;40:3351-63

[49] Ghisletti S.TCA-cycle metabolites in the nucleus: drivers of chromatin and epigenetic control.BMC Biol2025;23:316 PMCID:PMC12542002

[50] Li W,Wu H.Nuclear localization of mitochondrial TCA cycle enzymes modulates pluripotency via histone acetylation.Nat Commun2022;13:7414 PMCID:PMC9718843

[51] Morin A,Moog S.TET-mediated hypermethylation primes SDH-deficient cells for HIF2α-driven mesenchymal transition.Cell Rep2020;30:4551-66.e7

[52] Wang Z,Lv M,Li T.Novel histone modifications and liver cancer: emerging frontiers in epigenetic regulation.Clin Epigenetics2025;17:30 PMCID:PMC11841274

[53] Yuan T,Qian M.SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.Hepatology2023;78:103-19

[54] Verma A.The emerging intertwined activities of metabolism and epigenetics unveils culprits and prospects in cancer.Exp Mol Med2025;57:1928-39 PMCID:PMC12508213

[55] Fernández-Barrena MG,Colyn L,Avila MA.Epigenetics in hepatocellular carcinoma development and therapy: the tip of the iceberg.JHEP Rep2020;2:100167 PMCID:PMC7585149

[56] Wang P,Xiong Y.Metabolite regulation of epigenetics in cancer.Cell Rep2024;43:114815

[57] Zhao S,Henry RA.ATP-citrate lyase controls a glucose-to-acetate metabolic switch.Cell Rep2016;17:1037-52 PMCID:PMC5175409

[58] Cai Q,Dai Y,Zhang Q.ATP citrate lyase promotes the progression of hepatocellular carcinoma by activating the REGγ-proteasome pathway.Mol Carcinog2024;63:1874-91

[59] Petillo A,Koshal P,Bisaccia F.Extracellular citrate is a Trojan Horse for cancer cells.Front Mol Biosci2020;7:593866 PMCID:PMC7688668

[60] Wang G.Connections between metabolism and epigenetic modifications in cancer.Med Rev2021;1:199-221 PMCID:PMC10388788

[61] Yang C,Hensley CT.Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport.Mol Cell2014;56:414-24 PMCID:PMC4268166

[62] Owen OE,Hanson RW.The key role of anaplerosis and cataplerosis for citric acid cycle function.J Biol Chem2002;277:30409-12

[63] Ying M,Zhu X,Zeng S.Lactate and glutamine support NADPH generation in cancer cells under glucose deprived conditions.Redox Biol2021;46:102065 PMCID:PMC8321918

[64] Wang R,Thorne RF.LncRNA GIRGL drives CAPRIN1-mediated phase separation to suppress glutaminase-1 translation under glutamine deprivation.Sci Adv2021;7:eabe5708 PMCID:PMC7990344

[65] Huang Y,Zeng T.IFRD1 promotes tumor cells “low-cost” survival under glutamine starvation via inhibiting histone H1.0 nucleophagy.Cell Discov2024;10:57 PMCID:PMC11130292

[66] Zaidi N,Kuemmerle NB,Swinnen JV.Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids.Prog Lipid Res2013;52:585-9 PMCID:PMC4002264

[67] Ray U.Aberrant lipid metabolism in cancer cells - the role of oncolipid-activated signaling.FEBS J2018;285:432-43

[68] Kuhajda FP,Li JN,Frehywot GL.Synthesis and antitumor activity of an inhibitor of fatty acid synthase.Proc Natl Acad Sci U S A2000;97:3450-4 PMCID:PMC16260

[69] Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer.Cell Metab2013;18:153-61 PMCID:PMC3742569

[70] Menendez JA.Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis.Nat Rev Cancer2007;7:763-77

[71] Rysman E,Scheys K.De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation.Cancer Res2010;70:8117-26

[72] Liu Z,Wang W.CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing.Proc Natl Acad Sci U S A2023;120:e2302878120 PMCID:PMC10523454

[73] Patsoukis N,Chatterjee P.PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation.Nat Commun2015;6:6692 PMCID:PMC4389235

[74] Yu TCY,Zhang VX,Ng IOL.Lipid metabolism and immune response in hepatocellular carcinoma: interplay driving tumor progression.Cancer Heterog Plast2025;2:0006

[75] Ren M,Xia H,Bi F.Simultaneously targeting SOAT1 and CPT1A ameliorates hepatocellular carcinoma by disrupting lipid homeostasis.Cell Death Discov2021;7:125 PMCID:PMC8164629

[76] Sangineto M,Cavallone F,Loizzi D.Lipid metabolism in development and progression of hepatocellular carcinoma.Cancers2020;12:1419 PMCID:PMC7352397

[77] Oh MH,Zhao L.Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells.J Clin Invest2020;130:3865-84 PMCID:PMC7324212

[78] Zhang C,Herrmann A.STAT3 activation-induced fatty acid oxidation in CD8⁺ T effector cells is critical for obesity-promoted breast tumor growth.Cell Metab2020;31:148-61.e5 PMCID:PMC6949402

[79] Ma X,Liu L.CD36-mediated ferroptosis dampens intratumoral CD8⁺ T cell effector function and impairs their antitumor ability.Cell Metab2021;33:1001-12.e5 PMCID:PMC8102368

[80] Brown TP.Lactate/GPR81 signaling and proton motive force in cancer: role in angiogenesis, immune escape, nutrition, and Warburg phenomenon.Pharmacol Ther2020;206:107451

[81] Hossain F,Wyczechowska D.Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies.Cancer Immunol Res2015;3:1236-47 PMCID:PMC4636942

[82] Wu J,Jiang RT.Characterization of metabolic landscape in hepatocellular carcinoma.World J Gastrointest Oncol2021;13:1144-56 PMCID:PMC8465443

[83] Yang M,Pollard JW.Diverse functions of macrophages in different tumor microenvironments.Cancer Res2018;78:5492-503 PMCID:PMC6171744

[84] Lu M,Wang X.ACOT12-dependent alteration of acetyl-CoA drives hepatocellular carcinoma metastasis by epigenetic induction of epithelial-mesenchymal transition.Cell Metab2019;29:886-900.e5

[85] Hamabe A,Tanuma N.Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition.Proc Natl Acad Sci U S A2014;111:15526-31 PMCID:PMC4217454

[86] Lee JW,Jeong JW,Kim KW.Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions.Exp Mol Med2004;36:1-12

[87] Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230-3.

[88] Colegio OR, Chu NQ, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513:559-63.

[89] Lee KY,Hayden MS,Ghosh S.PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation.Science2005;308:114-8

[90] Sun X,Liu H.The diapause-like colorectal cancer cells induced by SMC4 attenuation are characterized by low proliferation and chemotherapy insensitivity.Cell Metab2023;35:1563-79.e8

[91] Sen N, Hara MR, Kornberg MD, et al. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat Cell Biol. 2008;10:866-73.

[92] Hon KW, Naidu R. Unveiling metabolic signatures as potential biomarkers in common cancers: insights from lung, breast, colorectal, liver, and gastric tumours. Biomolecules. 2025;15:1376.

[93] Yalcin A, Clem BF, Imbert-Fernandez Y, et al. 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell Death Dis. 2014;5:e1337.

[94] De Los Santos-Jiménez J, Campos-Sandoval JA, Alonso FJ, Márquez J, Matés JM. GLS and GLS2 glutaminase isoenzymes in the antioxidant system of cancer cells. Antioxidants. 2024;13:745.

[95] Soro-Arnáiz I,Cherkaoui S.GLUD1 determines murine muscle stem cell fate by controlling mitochondrial glutamate levels.Dev Cell2024;59:2850-65.e8

[96] Hao Y, Yi Q, XiaoWu X, WeiBo C, GuangChen Z, XueMin C. Acetyl-CoA: an interplay between metabolism and epigenetics in cancer. Front Mol Med. 2022;2:1044585.

[97] Lopes C, Pereira C, Medeiros R. ASCT2 and LAT1 contribution to the hallmarks of cancer: from a molecular perspective to clinical translation. Cancers. 2021;13:203.

[98] Zhao L,Liu X.UBR7 inhibits HCC tumorigenesis by targeting Keap1/Nrf2/Bach1/HK2 and glycolysis.J Exp Clin Cancer Res2022;41:330 PMCID:PMC9686014

[99] Romero R,Davidson SM.Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.Nat Med2017;23:1362-8 PMCID:PMC5677540

[100] Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739-44.

[101] Nicklin P, Bergman P, Zhang B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136:521-34.

[102] Wahi K.ASCT2: a potential cancer drug target.Expert Opin Ther Targets2019;23:555-8

[103] Dang L,Attar EC.IDH mutations in cancer and progress toward development of targeted therapeutics.Ann Oncol2016;27:599-608

[104] Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16:619-34.

[105] Spinelli JB, Yoon H, Ringel AE, Jeanfavre S, Clish CB, Haigis MC. Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass. Science. 2017;358:941-46.

[106] Liu J,Liu J.Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation.Nat Commun2025;16:1762 PMCID:PMC11839913

[107] Jin Q,Boulbes D.Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.Breast Cancer Res2010;12:R96 PMCID:PMC3046439

[108] Menendez JA,Mehmi I.Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.Proc Natl Acad Sci U S A2004;101:10715-20 PMCID:PMC490000

[109] Zhang H, Chen H, Yin S, et al. Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitin-proteasome degradation. J Nutr Biochem. 2023;112:109186.

[110] Chen G, Bao B, Cheng Y, et al. Acetyl-CoA metabolism as a therapeutic target for cancer. Biomed Pharmacother. 2023;168:115741.

[111] Gu L,Larson-Casey JL.Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling.Cell Death Differ2022;29:118-32 PMCID:PMC8738732

[112] Yu X, Wu H, Su J, et al. Acetyl-CoA metabolism maintains histone acetylation for syncytialization of human placental trophoblast stem cells. Cell Stem Cell. 2024;31:1280-97.e7.

[113] Icard P,Fournel L,Lincet H.ATP citrate lyase: a central metabolic enzyme in cancer.Cancer Lett2020;471:125-34

[114] Snaebjornsson MT, Janaki-Raman S, Schulze A. Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer. Cell Metab. 2020;31:62-76.

[115] Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218:e20201606.

[116] Chen XF, Tian MX, Sun RQ, et al. SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer. EMBO Rep. 2018;19:e45124.

[117] Ding X, Shao L, Wang J, Jin Y, Chen H, Li B. HADHA promotes esophageal cancer progression by activating mTOR signaling and the SP1/MDM2 axis. Acta Biochim Biophys Sin. 2024;57:378-88.

[118] Ye J,Liao Z.Single cell-spatial transcriptomics and bulk multi-omics analysis of heterogeneity and ecosystems in hepatocellular carcinoma.NPJ Precis Oncol2024;8:262 PMCID:PMC11568154

[119] Li Y,Sun H.Spatial transcriptomics and snRNA-seq expose CAF niches orchestrating dual stromal-immune barriers in hepatocellular carcinoma.Adv Sci2025;12:e14661 PMCID:PMC12752642

[120] Tong W,Bai Y.Spatial transcriptomics reveals tumor-derived SPP1 induces fibroblast chemotaxis and activation in the hepatocellular carcinoma microenvironment.J Transl Med2024;22:840 PMCID:PMC11391636

[121] Liu Y,Ma K.Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.J Hepatol2023;78:770-82

[122] Fan G,Li L,Han X.Single-cell and spatial analyses revealed the co-location of cancer stem cells and SPP1+ macrophage in hypoxic region that determines the poor prognosis in hepatocellular carcinoma.NPJ Precis Oncol2024;8:75 PMCID:PMC10960828

[123] Su R,Tian P,Hui Y.Single-cell and spatial transcriptomics reveal correlation between RNA methylation-related miRNA risk model and immune infiltration in hepatocellular carcinoma.Front Oncol2025;15:1553239 PMCID:PMC12098086

[124] Xu WX,Chen JL.SPP1+ tumor-associated macrophages define a high-risk subgroup and inform personalized therapy in hepatocellular carcinoma.Front Oncol2025;15:1606195 PMCID:PMC12259448

[125] Wang Y,Tang W.Hepatocellular carcinoma cells induce regulatory T cells and lead to poor prognosis via production of transforming growth factor-β1.Cell Physiol Biochem2016;38:306-18

[126] Gu J,Chen Q.Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells.Cell Rep2022;39:110986

[127] Zhou Y,Wan T.ZEB1 enhances Warburg effect to facilitate tumorigenesis and metastasis of HCC by transcriptionally activating PFKM.Theranostics2021;11:5926-38 PMCID:PMC8058737

[128] Kumagai S,Itahashi K.Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.Cancer Cell2022;40:201-18.e9

[129] Chivite-Lacaba M,Utrero-Rico A.Delineation of monocytic and early-stage myeloid-derived suppressor cells in the peripheral blood of patients with hepatocarcinoma.Int J Cancer2025;156:2416-28 PMCID:PMC12008823

[130] Iwata T,Kimura O.PD-L1⁺MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment.Sci Rep2016;6:39296 PMCID:PMC5155242

[131] Hoechst B,Ballmaier M.A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4⁺CD25⁺Foxp3⁺ T cells.Gastroenterology2008;135:234-43

[132] Yang X,Hang J.Lactate-modulated immunosuppression of myeloid-derived suppressor cells contributes to the radioresistance of pancreatic cancer.Cancer Immunol Res2020;8:1440-51

[133] Wang H,Qin W,Li X.Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies.Theranostics2025;15:2159-84 PMCID:PMC11840731

[134] Yang Y,To KKW,Wang F.Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy.J Exp Clin Cancer Res2025;44:145 PMCID:PMC12083052

[135] Huang D,Wang L.Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress.Cell Res2016;26:1112-30 PMCID:PMC5113304

[136] Chang CH, Curtis JD, Maggi LB Jr, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis.Cell2013;153:1239-51 PMCID:PMC3804311

[137] Elia I,Johnson S.Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8⁺ T cells.Cell Metab2022;34:1137-50.e6 PMCID:PMC9357162

[138] Xia C,To KKW.CD39/CD73/A2AR pathway and cancer immunotherapy.Mol Cancer2023;22:44 PMCID:PMC9979453

[139] Xu S,Rodríguez-Morales P.Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8⁺ T cells in tumors.Immunity2021;54:1561-77.e7 PMCID:PMC9273026

[140] Guo C,Shi H.SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity.Nature2023;620:200-8 PMCID:PMC10396969

[141] Pallotta MT,Suvieri C.Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme.FEBS J2022;289:6099-118 PMCID:PMC9786828

[142] Cubillos-Ruiz JR,Rutkowski MR.ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis.Cell2015;161:1527-38 PMCID:PMC4580135

[143] Veglia F,Mohammadyani D.Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer.Nat Commun2017;8:2122 PMCID:PMC5730553

[144] Binnewies M,Kersten K.Understanding the tumor immune microenvironment (TIME) for effective therapy.Nat Med2018;24:541-50 PMCID:PMC5998822

[145] Xiang H,Tu J.Metabolic reprogramming of immune cells in pancreatic cancer progression.Biomed Pharmacother2023;157:113992

[146] Xie Z,Li Y.Single-cell RNA sequencing revealed potential targets for immunotherapy studies in hepatocellular carcinoma.Sci Rep2023;13:18799 PMCID:PMC10620237

[147] Wang K,Guo S.Metabolic reprogramming of glucose: the metabolic basis for the occurrence and development of hepatocellular carcinoma.Front Oncol2025;15:1545086 PMCID:PMC11839411

[148] Wang JX,Niu X.Lactic acid and an acidic tumor microenvironment suppress anticancer immunity.Int J Mol Sci2020;21:8363 PMCID:PMC7664620

[149] Tannahill GM,Adamik J.Succinate is an inflammatory signal that induces IL-1β through HIF-1α.Nature2013;496:238-42 PMCID:PMC4031686

[150] Quail DF.Molecular pathways: deciphering mechanisms of resistance to macrophage-targeted therapies.Clin Cancer Res2017;23:876-84 PMCID:PMC5453188

[151] Kouidhi S,Benammar Elgaaied A.Targeting tumor metabolism: a new challenge to improve immunotherapy.Front Immunol2018;9:353 PMCID:PMC5829092

[152] Yang L,Liu M.Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy.J Hematol Oncol2023;16:59 PMCID:PMC10240810

[153] Morchón-Araujo D,Mirallas O.Emerging immunotherapy targets in early drug development.Int J Mol Sci2025;26:5394 PMCID:PMC12155519

[154] Pavlova NN.The emerging hallmarks of cancer metabolism.Cell Metab2016;23:27-47 PMCID:PMC4715268

[155] Jin H, Wu P, Lv C, et al. Mannose inhibits PKM2 lactylation to induce pyroptosis in bladder cancer and activate antitumor immune responses. Commun Biol. 2025;8:689.

[156] Stein M,Jeyamohan C.Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies.Prostate2010;70:1388-94 PMCID:PMC4142700

[157] Wang R,Zhang Q.Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies.Exp Hematol Oncol2025;14:99 PMCID:PMC12282028

[158] Escutia-Gutiérrez R,Rodriguez-Fragoso L.Effect of gallic acid on preneoplastic liver lesions in vivo.FASEB J2016;30:1268.7

[159] Li P,Lv L.The role of gallic acid in liver disease: a review of its phytochemistry, pharmacology, and safety.Front Pharmacol2025;16:1595508 PMCID:PMC12331682

[160] Woodford MR,Backe SJ,Mollapour M.Structural and functional regulation of lactate dehydrogenase-A in cancer.Future Med Chem2020;12:439-55

[161] Benyahia Z,Hamelin L.In vitro and in vivo characterization of MCT1 inhibitor AZD3965 confirms preclinical safety compatible with breast cancer treatment.Cancers2021;13:569 PMCID:PMC7867268

[162] Noble RA,Blair H.Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.Haematologica2017;102:1247-57 PMCID:PMC5566036

[163] Gouda MA,Tawbi H.A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer.ESMO Open2025;10:104536 PMCID:PMC12141888

[164] Chen Y,Bajor DL,Selfridge JE.A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues.J Genet Genomics2020;47:389-95 PMCID:PMC7704934

[165] Cluntun AA,Cerione RA.Glutamine metabolism in cancer: understanding the heterogeneity.Trends Cancer2017;3:169-80 PMCID:PMC5383348

[166] Zhang Y,Xie L.The glutaminase-1 inhibitor [¹¹C-carbony]BPTES: synthesis and positron emission tomography study in mice.Pharmaceuticals2023;16:963 PMCID:PMC10384602

[167] Cervantes-Madrid D,Dueñas-González A.Reviving lonidamine and 6-diazo-5-oxo-L-norleucine to be used in combination for metabolic cancer therapy.Biomed Res Int2015;2015:690492 PMCID:PMC4575731

[168] Bell BJ,Deme P.Glutamine antagonist JHU083 improves psychosocial behavior and sleep deficits in EcoHIV-infected mice.Brain Behav Immun Health2022;23:100478 PMCID:PMC9207540

[169] Falchook G,Arkenau HT.First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors.EClinicalMedicine2021;34:100797 PMCID:PMC8040281

[170] Chen S,Zhang A.The ups, downs and new trends of IDO1 inhibitors.Bioorg Chem2021;110:104815

[171] Naing A,Pishvaian MJ.First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours.BMJ Oncol2024;3:e000249 PMCID:PMC11235002